Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report

• Main Authors: Kazumi Nishino (Author), Kei Kunimasa (Author), Madoka Kimura (Author), Takako Inoue (Author), Motohiro Tamiya (Author), Hanako Kuhara (Author), Toru Kumagai (Author)
• Format: Book
• Published: BMC, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Pulmonary sarcomatoid carcinoma is a rare non-small-cell lung cancer (NSCLC) subtype with a poor prognosis. In the phase III PACIFIC study, durvalumab significantly improved progression-free survival and overall survival versus placebo, in patients with stage III NSCLC who do not...